在过去的几年里，人们对免疫疗法在局部晚期 (LA) 和复发性和转移性头颈鳞状细胞癌 (R/M HNSCC) 中的作用越来越感兴趣。老年人群缺乏前瞻性试验的高质量数据。本系统综述和荟萃分析旨在综述免疫治疗在老年患者中的疗效和安全性。进行了系统的文献检索。提供老年人亚组（> 65 岁）结果数据的随机临床试验可用于荟萃分析。感兴趣的主要结局是用于疗效分析的 OS 和 PFS。系统评价中纳入了七项研究，疗效分析中纳入了四项研究。 OS 和 PFS 的汇总分析显示出一致的益处（HR 分别为 0.78 和 0.91）。免疫疗法可能是老年人群中有效且耐受性良好的治疗选择，但需要更多前瞻性和随机数据。PROSPERO (CRD42022333891)。版权所有 © 2024 Salvestrini、Caini、Scricciolo、Saerens、Bollen、Bonomo、Caparrotti、Lorini、Oliva、Urbanowicz-Nijaki 和 Szturz。

Over the past years, there has been a growing interest in the role of immunotherapy in locally advanced (LA) and recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). High-quality data from prospective trials are lacking for the elderly subpopulation. This systematic review and meta-analysis aims to review the efficacy and safety of immunotherapy in older patients.A systematic literature search was conducted. Randomized clinical trials providing outcome data on a subgroup of elderly (>65 years old) were available for meta-analysis. Primary outcomes of interest were OS and PFS for efficacy analysis.Seven studies were included in the systematic review and four in the efficacy analysis. The pooled analysis of OS and PFS showed a consistent benefit (HR 0.78 and 0.91, respectively).Immunotherapy may be an effective and well-tolerated treatment option in the elderly population, but more prospective and randomized data are needed.PROSPERO (CRD42022333891).Copyright © 2024 Salvestrini, Caini, Scricciolo, Saerens, Bollen, Bonomo, Caparrotti, Lorini, Oliva, Urbanowicz-Nijaki and Szturz.